Tacrolimus Therapeutic
Mostrando 1-11 de 11 artigos, teses e dissertações.
-
1. Periorbital discoid lupus: a rare localization in a patient with systemic lupus erythematosus
Abstract A 40-year-old female patient with a 5-year history of systemic lupus erythematosus was referred to our policlinic with complaints of erythema, atrophy, and telangiectasia on the upper eyelids for 8 months. No associated mucocutaneous lesion was present. Biopsy taken by our ophthalmology department revealed discoid lupus erythematosus. Topical tacrol
An. Bras. Dermatol.. Publicado em: 2016-10
-
2. Granuloma faciale: a good therapeutic response with the use of topical tacrolimus
AbstractGranuloma faciale is a rare dermatosis of chronic course, benign, usually asymptomatic, first described in 1945 by Wingley. It is characterized by the appearance of well-defined, single or multiple papules, plaques and nodules, predominantly located in sun-exposed areas, especially the face. In this work we report the case of a female patient, 58 yea
An. Bras. Dermatol.. Publicado em: 2015-10
-
3. An analysis of tacrolimus-related complications in the first 30 days after liver transplantation
OBJECTIVES: Orthotopic liver transplantation has improved survival in patients with end-stage liver disease; however, therapeutic strategies that achieve ideal immunosuppression and avoid early complications are lacking. To correlate the dose and level of Tacrolimus with early complications, e.g., rejection, infection and renal impairment, after liver trans
Clinics. Publicado em: 2014-11
-
4. Análise de custo-efetividade dos inibidores da rapamicina para o tratamento de imunossupressão no transplante renal
Terminal chronic kidney disease can be treated with hemodialysis (HD), peritoneal dialysis (PD) or by means of renal transplantation. Among these three treatment modalities, the transplant is, according to the literature, the modality that offers better quality of life. Adding to this the progress of the immunosuppressants used in post-transplant, the number
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 15/06/2012
-
5. Análise clínica evolutiva do uso do tacrolimus como droga imunossupressora em transplante cardíaco pediátrico / Clinical outcome of tacrolimus as maintenance immunosuppressive drug in pediatric heart transplantation
O Tacrolimus é uma potente droga imunossupressora introduzida no transplante cardíaco no início da década de 90. Pacientes com rejeição refratária ou intolerância à ciclosporina podem responder à terapia de resgate com o tacrolimus. Os objetivos deste estudo foram: avaliar a evolução clínica das crianças submetidas ao transplante cardíaco que
Publicado em: 2011
-
6. Assessment of the bioavailability of a new micophenolate mofetil formulation and a method for therapeutic monitoring / Avaliação da biodisponibilidade de uma nova formulação de micofenolato mofetil e de um método para sua monitorização terapêutica
O Micofenolato Mofetil (MMF) é amplamente utilizado em transplantes de órgãos sólidos e tem como seu metabólito ativo o ácido micofenólico (MPA). A alta variabilidade intra e interindividual dos níveis plasmáticos de MPA em pacientes transplantados renais que recebem a mesma dose de MMF, a combinação com diferentes imunossupressores que afetam seu
Publicado em: 2007
-
7. "Co-interferências da farmacocinética dos inibidores de calcineurina em associação com micofenolato mofetil em pacientes transplantados renais" / Interferences of calcineurin inhibitors on the pharmacokinetics of mycophenolic acid in renal transplantation
To evaluate the exposure to mycophenolic acid (MPA) early after renal transplantation, recipients were allocated to tacrolimus (n = 33) or Neoral (n =19, control) plus MMF. Pharmacokinetic curves (AUC) of calcineurin inhibitor and MPA were drawn on days 7, 14, 30, 60 and 180 post-transplant. From days 14-180, MPA-AUC was higher in tacrolimus group due to a h
Publicado em: 2006
-
8. Tacrolimus Ameliorates Metabolic Disturbance and Oxidative Stress Caused by Hepatitis C Virus Core Protein : Analysis Using Mouse Model and Cultured Cells
Hepatic steatosis and insulin resistance are factors that aggravate the progression of liver disease caused by hepatitis C virus (HCV) infection. In the pathogenesis of liver disease and metabolic disorders in HCV infection, oxidative stress due to mitochondrial respiratory chain dysfunction plays a pivotal role. Tacrolimus (FK506) is supposed to protect mit
American Society for Investigative Pathology.
-
9. T-Cell Receptor-Stimulated Calcineurin Activity Is Inhibited in Isolated T Cells from Transplant Patients
The addition of calcineurin inhibitors, including cyclosporine A (CsA) and FK-506 (tacrolimus), to transplant protocols has markedly reduced acute allograft rejection and prolonged patient survival. Although monitoring of serum drug levels has been shown to be a poor indicator of efficacy, there is little data on calcineurin enzymatic activity in humans.
American Society for Pharmacology and Experimental Therapeutics.
-
10. Ergosterol Biosynthesis Inhibitors Become Fungicidal when Combined with Calcineurin Inhibitors against Candida albicans, Candida glabrata, and Candida krusei
Azoles target the ergosterol biosynthetic enzyme lanosterol 14α-demethylase and are a widely applied class of antifungal agents because of their broad therapeutic window, wide spectrum of activity, and low toxicity. Unfortunately, azoles are generally fungistatic and resistance to fluconazole is emerging in several fungal pathogens. We recently established
American Society for Microbiology.
-
11. Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans
Cryptococcus neoformans is an opportunistic fungal pathogen that causes life-threatening infections of the central nervous system. Existing therapies include amphotericin B, fluconazole, and flucytosine, which are limited by toxic side effects and the emergence of drug resistance. We recently demonstrated that the protein phosphatase calcineurin is required
American Society for Microbiology.